Aldeyra Therapeutics, Inc. (ALDX) has a negative trailing P/E of -2.7, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 25.6 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -36.47%, forward earnings yield 3.91%. PEG 0.18 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
Overall SharesGrow Score: 58/100 with 3/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | -3.2 | -0.18 | 2.81 | 0.00 | - |
| 2017 | -4.8 | 0.32 | 2.73 | 0.00 | - |
| 2018 | -4.6 | -0.17 | 2.08 | 0.00 | - |
| 2019 | -2.6 | -0.10 | 3.28 | 0.00 | - |
| 2020 | -6.2 | 0.12 | 3.92 | 0.00 | - |
| 2021 | -3.7 | 1.04 | 1.05 | 0.00 | - |
| 2022 | -6.6 | 7.01 | 2.69 | 0.00 | - |
| 2023 | -5.5 | 0.14 | 1.73 | 0.00 | - |
| 2024 | -5.3 | -0.11 | 4.18 | 0.00 | - |
| 2025 | -9.2 | 0.23 | 7.03 | 0.00 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $-1.65 | $0.00 | $-18.7M | - |
| 2017 | $-1.40 | $0.00 | $-22.34M | - |
| 2018 | $-1.79 | $0.00 | $-38.89M | - |
| 2019 | $-2.24 | $0.00 | $-60.83M | - |
| 2020 | $-1.11 | $0.00 | $-37.55M | - |
| 2021 | $-1.10 | $0.00 | $-57.78M | - |
| 2022 | $-1.05 | $0.00 | $-61.37M | - |
| 2023 | $-0.64 | $0.00 | $-37.54M | - |
| 2024 | $-0.94 | $0.00 | $-55.85M | - |
| 2025 | $-0.56 | $0.00 | $-33.85M | - |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $0.07 | $-0.04 – $0.18 | $58.04M | $53.89M – $62.18M | 3 |
| 2027 | $-0.26 | $-0.37 – $-0.14 | $23.68M | $21.05M – $26.3M | 3 |
| 2028 | $1.14 | $0.27 – $2.21 | $199.72M | $185.45M – $213.98M | 3 |
| 2029 | $1.75 | $1.58 – $1.91 | $171.4M | $159.16M – $183.64M | 1 |
| 2030 | $2.38 | $2.16 – $2.60 | $210.77M | $195.72M – $225.81M | 1 |
